Haemonetics Co. (NYSE:HAE) Stock Holdings Raised by Geode Capital Management LLC

Geode Capital Management LLC grew its position in Haemonetics Co. (NYSE:HAE - Free Report) by 1.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,193,927 shares of the medical instruments supplier's stock after purchasing an additional 21,547 shares during the quarter. Geode Capital Management LLC owned about 2.38% of Haemonetics worth $95,986,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Raymond James & Associates grew its position in shares of Haemonetics by 88.9% during the 2nd quarter. Raymond James & Associates now owns 16,951 shares of the medical instruments supplier's stock worth $1,402,000 after purchasing an additional 7,979 shares in the last quarter. Legato Capital Management LLC grew its position in Haemonetics by 8.2% during the second quarter. Legato Capital Management LLC now owns 8,088 shares of the medical instruments supplier's stock worth $669,000 after buying an additional 614 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Haemonetics by 41.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,258 shares of the medical instruments supplier's stock worth $931,000 after acquiring an additional 3,274 shares during the period. Crossmark Global Holdings Inc. raised its holdings in Haemonetics by 31.1% in the 2nd quarter. Crossmark Global Holdings Inc. now owns 9,998 shares of the medical instruments supplier's stock valued at $827,000 after acquiring an additional 2,370 shares in the last quarter. Finally, Fort Washington Investment Advisors Inc. OH lifted its position in shares of Haemonetics by 28.5% during the 2nd quarter. Fort Washington Investment Advisors Inc. OH now owns 229,663 shares of the medical instruments supplier's stock valued at $19,000,000 after acquiring an additional 50,902 shares during the period. Institutional investors own 99.67% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on HAE. Citigroup dropped their price target on Haemonetics from $94.00 to $85.00 and set a "neutral" rating for the company in a research note on Thursday, August 22nd. Raymond James upgraded shares of Haemonetics from an "outperform" rating to a "strong-buy" rating and set a $120.00 price objective for the company in a report on Friday, November 8th. CL King started coverage on Haemonetics in a report on Friday, September 13th. They set a "buy" rating and a $116.00 target price on the stock. Barrington Research reiterated an "outperform" rating and set a $108.00 price objective on shares of Haemonetics in a research report on Wednesday, December 4th. Finally, BTIG Research began coverage on Haemonetics in a report on Tuesday, September 10th. They issued a "buy" rating and a $112.00 price target on the stock. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $108.78.

Haemonetics Stock Performance

Haemonetics stock traded down $1.46 during trading hours on Friday, hitting $75.44. 1,502,820 shares of the stock traded hands, compared to its average volume of 555,120. The stock has a market capitalization of $3.79 billion, a price-to-earnings ratio of 31.30, a P/E/G ratio of 1.29 and a beta of 0.38. Haemonetics Co. has a 1 year low of $70.25 and a 1 year high of $97.97. The firm's 50 day moving average price is $81.38 and its 200-day moving average price is $81.35. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.49 and a quick ratio of 2.09.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.09 by $0.03. The firm had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The company's quarterly revenue was up 8.6% on a year-over-year basis. During the same period last year, the company earned $0.99 EPS. As a group, equities analysts expect that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.